News archive

Filter by: Reset

March 2015

- March 3, 2015
- Crown Bioscience
Crown Bioscience Launches Life Science Product Catalog

TOOLS TO SUPPORT PRECLINICAL RESEARCH, DRUG DEVELOPMENT AND VALIDATION

- February 26, 2015
- KBI Biopharma
JSR Corporation and KBI Biopharma, Inc. Agree to Acquisition; INCJ and CMIC of Japan also participate

JSR continues to demonstrate its commitment to the life sciences industry, by expanding its bioprocess capabilities and gaining a strong, successful partner.
- February 12, 2015
- Crown Bioscience
Crown Bioscience Acquires Molecular Response’s Patient Derived Xenograft (PDX) Business

Crown is acquiring all of Molecular Response’s existing PDX models as well as 8,000 viable human tumors for model development from Molecular Response’s viable tumor bank of over 140,000 unique cryo...

- January 22, 2015
- KBI Biopharma
Selexis-Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing

Selexis SA is the First biotechnology Company to Deliver Manufacturing-Ready Research Cell Banks with a Fully Sequenced Genome and Transcriptome
- January 15, 2015
- Crown Bioscience
Crown Bioscience Announces First European Symposium on Translational Oncology and the use of Patient-Derived Xenograf...

KEY OPINION LEADERS TO DISCUSS THE USE OF TRANSLATIONAL PLATFORMS IN ACCELERATING ONCOLOGY DRUG DISCOVERY
- January 8, 2015
- KBI Biopharma
First Selexis SUREtechnology-Generated Therapeutic Monoclonal Antibody Approved for Market

The Selexis SURE CHO-M Cell Line™ is a proprietary high-performance mammalian cell line derived from CHO-K1 cells.

- December 9, 2014
- KBI Biopharma
Symphogen A/S Licenses the Selexis SUREtechnology Expression Platform and Cell Line

Symphogen has developed unique technologies for the controlled, reproducible production of highly characterized MAb mixtures manufactured in a single batch.

- October 20, 2014
- Crown Bioscience
Crown Bioscience Announces U.S. Expansion With New Translational Oncology Center

NEW SERVICE CENTER WILL ALLOW THE EXPANSION OF NEW IMMUNOTHERAPY EXPERIMENTAL PLATFORMS TO ADVANCE TRANSLATIONAL MEDICAL RESEARCH AND THE TREATMENT OF CANCERS

- August 14, 2014
- Crown Bioscience
Crown Bioscience Announces Inaugural Symposium to Foster Greater Understanding of Predictive Models in Oncology

INDUSTRY LEADERS WILL DISCUSS USE OF PATIENT-DERIVED XENOGRAFT MODELS TO HELP ACCELERATE ONCOLOGY DRUG DISCOVERY

- June 24, 2014
- KBI Biopharma
Cook Pharmica, LLC and Selexis SA Establish Customized Biologic Drug Development and Manufacturing Services Platform

Preliminary Data from the Successful Proof-of-Concept Program Published in the June Issue of BioProcess International

- May 15, 2014
- Crown Bioscience
Crown Bioscience receives $26.55 million in Series D Funding

INVESTMENT TO FUND RAPID EXPANSION IN TRANSLATIONAL PLATFORM TECHNOLOGIES FOR ONCOLOGY AND METABOLIC DISEASES
- May 8, 2014
- Crown Bioscience
Crown Bioscience Announces Research Collaboration with the National Resource Center for Mutant Mice (NRCMM)

NEW COLLABORATION AIMS TO DEVELOP DISEASE-SPECIFIC EXPERIMENTAL MODELS FOR TRANSLATIONAL MEDICAL RESEARCH

21 of 23